ImmunoGen, Inc.
IMGN
NASDAQ4.75
ImmunoGen, Inc.
NASDAQ:IMGN
RECENT
PRICE
4.75
P/E
RATIO
-5.99
(PEG:- -)
P/E RATIO
RELATIVE
TO S&P
-0.30
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.89 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 01/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
0.78
(0.43)
(0.40)
- -
0.92
(0.45)
(0.43)
- -
0.94
(0.75)
(0.89)
- -
0.55
(0.63)
(0.30)
- -
0.24
(0.87)
(0.72)
- -
0.28
(0.85)
(0.15)
- -
0.21
(0.95)
(0.48)
- -
0.42
(0.87)
(0.76)
- -
0.70
(0.83)
(0.72)
- -
0.99
(0.71)
(0.73)
- -
0.69
(1.67)
(1.55)
- -
1.18
(0.98)
0.07
- -
0.38
(1.21)
(1.23)
- -
0.55
(0.70)
(0.62)
- -
0.75
(0.25)
(0.45)
- -
0.34
(0.68)
(0.83)
- -
0.39
(0.82)
(0.89)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.05
1.76
0.05
1.40
0.42
1.29
0.04
1.31
0.03
1.73
0.03
2.03
0.04
1.09
0.04
1.45
0.10
0.89
0.09
0.41
0.12
(0.95)
0.01
(0.18)
0.04
0.08
0.02
(0.51)
0.01
0.51
0.01
1.58
0.01
1.09
CAPEX per share
Book Value per share
41
42
43
51
59
69
77
84
85
86
87
98
140
148
176
206
244
Comm.Shares outs.(m)
- -
- -
- -
(11.0)
(0.6)
- -
(5.2)
(0.2)
- -
(11.5)
(0.2)
- -
(9.2)
(0.4)
- -
(13.3)
(0.8)
- -
(14.6)
(1.0)
- -
(18.6)
(1.1)
- -
(14.7)
(0.8)
- -
(16.0)
(0.8)
- -
(3.0)
(0.1)
- -
(5.3)
(0.2)
- -
(7.6)
(0.3)
- -
(4.6)
(0.2)
- -
(18.6)
(0.5)
- -
(10.2)
(0.3)
- -
(6.0)
(0.3)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/9/22 | Q3)
Total liabilities
$181 m.
Total assets
$359 m.
Long-term debt
$12 m.
Cash and equiv.
$310 m.
Goodwill - -
Retained earnings $(1,635) m.
Common stock 254 m. shares
Market Capitalisation
$1,049 m. (as of 29/1/23)
19
(311.8)%
16
(447.9)%
36
(205.5)%
60
(119.4)%
86
(63.7)%
60
(208.3)%
115
(51.1)%
53
(302.1)%
82
(112.0)%
132
(16.9)%
70
(179.0)%
96
(279.5)%
Revenue (m)
Operating margin
5
(58)
5
(73)
5
(73)
5
(71)
6
(61)
5
(145)
6
(96)
7
(169)
4
(104)
2
(44)
2
(139)
2
(201)
Depreciation (m)
Net profit (m)
- -
(301.9)%
- -
(448.2)%
- -
(204.9)%
- -
(119.1)%
- -
(71.0)%
- -
(241.4)%
- -
(83.2)%
- -
(315.9)%
- -
(126.6)%
- -
(33.5)%
- -
(199.4)%
- -
(285.0)%
Income tax rate
Net profit margin
187
- -
140
150
- -
84
182
- -
122
130
- -
76
256
- -
35
193
100
(82)
221
2
(18)
208
2
11
131
2
(76)
202
19
90
399
15
326
227
12
178
Working capital (m)
Long-term debt (m)
Equity (m)
(28.7)%
(26.8)%
(41.6)%
(44.7)%
(40.7)%
(87.4)%
(37.4)%
(34.1)%
(59.8)%
(49.5)%
(43.2)%
(94.3)%
(19.9)%
(17.6)%
(173.0)%
(55.3)%
(43.4)%
176.0%
(33.2)%
(26.9)%
536.5%
(70.4)%
(53.5)%
(1,538.9)%
(55.2)%
(37.0)%
136.8%
(9.1)%
(6.0)%
(49.5)%
(29.7)%
(24.0)%
(42.8)%
(76.7)%
(54.6)%
(113.0)%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
176
294
479
Receivables
27
22
14
Inventory
- -
- -
- -
Other
5
8
7
Current assets
209
324
500
Acc. Payable
10
10
18
Debt due
3
5
4
Other
65
108
79
Current liab.
77
122
101
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
ImmunoGen, Inc. (US) started trading on November 5, 1989 (cik: 0000855654), operates in the Healthcare sector (Biotechnology industry), has 106 full-time employees, and is led by Mr. Mark Enyedy. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
3.46%
33.89%
Cash flow
-668.54%
-288.20%
Earnings
48.52%
31.25%
Dividends
- -
- -
Book value
-227.31%
-152.03%
Insider trading
Type
Shares
Date
Mccain Tracey L
Award
2,772
12/30/22
Mitchell Dean J
Award
3,024
12/30/22
Goldberg Mark Alan
Award
3,402
12/30/22
Berkenblit Anna
Award
436
12/30/22
Wingrove Theresa
Award
1,131
12/30/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
13
15
18
86
132
2021
16
17
9
28
70
2022
38
14
15
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
(0.17)
(0.14)
(0.13)
0.18
-0.25
2021
(0.17)
(0.15)
(0.18)
(0.18)
-0.68
2022
(0.10)
(0.24)
(0.31)
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
02/15/2022
Virgin Galactic, Tower Semiconductor, CrowdStrike, Bitcoin: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...